Heart Tumor Market – An Immortal Market with a Stunning CAGR of ~7.1% by 2023

“Market Research Future”
In the coming years, it is expected that the Global Heart Tumor Market will advance with higher growth rate as compared to previous years. Rising pressure to curb healthcare costs has fuelled the growth of the market for Heart Tumor market.

MarketResearchFuture.com adds “Heart Tumor Market -2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database.

Global Heart Tumor Market by Manufacturers, Countries, Type and Application, Forecast to 2023 Report “Provides In-Depth Analysis of Parent Market Trends, Macro-Economic Indicators and Governing Factors Along With Market Attractiveness as Per Segments. The global market of Heart Tumor is expected to grow at a CAGR of approximately ~7.1% during the forecast period 2017-2023.

Key Players:

Some of key the players in the Global heart tumor market are Tomtec Imaging Systems GmBh, Koninklijke Philips N.V., Siemens Healthineers, Circle Cardiovascular Imaging Inc., Toshiba Corporation, Shimadzu Corporation, CardioComm Solutions Inc., Integer Holdings Corporation, Pie Medical Imaging, HeartSciences, 3mensio Medical Imaging, and eMedica, S.L.

Market Scenario:

Cardiac tumors is a rare disease that aredifficult to diagnose. They are divided on the basis of type into primary and secondary tumors. The prevalance of the secondary tumors is higher than the primary tumors. Majority of the primary cardiac tumors are benign in origin. The high incidences of metastatic tumors is attributed to various types of cancers such as lung, breast, renal cancer, lymphomas and melanomas. Clinical manifestations of these tumors generally based on the size and location of the tumors and spread to the adjacent tissues rather than the type of the tumor itself.  Echocardiography is the major tool used for diagnosis of the tumors. Other imaging modalities include cardiac MRI, cardiac CT, and 3D echocardiography, which may offer some additional information with histological examination.

According to the surgery and autopsy reports, primary cardiac tumors are rare with an incidence rate of about 0.3%-0.7%. Malignant primary cardiac sarcomas are usually located in the right atrium of the heart and are most commonly angiosarcomas. The malignant primary cardiac tumors are often diagnosed in young patientswho have a poor prognosis and survival rate of only 10% According to the WHO, the prevalence of melanoma skin cancers has been increasing from the past few decades. Furthermore, 132,000 melanoma skin cancers cases are reported each year across the globe.

A small percentage of cardiac tumor cases are hereditary, the tumors can also be associated with another health condition, such as LAMB Syndrome, Carney Syndrome or NAME Syndrome. However, most often, the tumor develops without being associated with any health condition or presence of a family history. They result from cell overgrowth but mostly cardiac tumors results from metastatic condition, where cells from other cancerous organ such as lung and breast, soft-tissues and metastasizes to the heart.

Myxoma is the most common primary cardiac tumor accounting for 50% of all the cardiac tumors. Incidences of myxoma in women is 2 to 4 times more than men. About 75% of myxomas occur in the left atrium and the rest occur in the other chambers as a solid tumor or, less commonly, at several other sites. Myxomas can grow upto 15 cm in diameter.

Removal requires open heart surgery and in many cases it can be done robotically or using a minimally invasive technique. The hospital stay is likely to be shorten if sugery is done robotically or by minimally invasive approach.  Successful recovery is rare. After surgery, echocardiogram is required to be done every year to make sure that the tumor has not returned and that there are no new growth.

The global heart tumor market is expected to grow at a CAGR of approximately 7.1% during the forecast period 2017-2023.


The heart tumor is segmented on the basis of type, diagnosis, treatment.

On the basis of the type, the market is segmented into primary tumors and secondary tumors. The primary tumors are divided into benign and malignant. The benign tumors is further categorized into myxoma, papillary heart tumors, fibromas, rhabdomyomas, angioma, and lipomas. The malignant tumors are divided into rhabdomyosarcoma, mesenchymomas, neurosarcoma, fusiform cell tumors, malignant heart hemangioma, and lymphosarcoma. The secondary tumor is categorized into metastatic and contiguity. The metastatic secondary tumors are divided into hematogenic and lymphatic and the contiguity is sub categorized into mediastinal tumors, lung tumors and oesophageal, or cardia tumor.

On the basis of the diagnosis, the market is classified into echocardiogram, Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), radionuclide imaging, Position Emission Tomography (PET) Scan, myocardial biopsy, cardiac catherization, and electrophysiology test.

On the basis of the treatment, the market is classified into surgery, chemotherapy, radiation therapy. Furthermore, the surgery is further categorized into open heart surgery, minimal invasive surgery, and heart transplant surgery

GET SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/5065 .

Regional Analysis

The global heart tumor market consists of four major regions: the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Americas dominate the market owing to the rising awareness among people and increasing healthcare expenditure. The type of tumors also aids in selection of treatment procedure. For instance, in patient with heart cancers, the results of cardiac imaging could be used to see if the the tumor is spread to the adjacent tissues, which can be further used to remove the portion by performing excision surgery or pursuing treatment with medications.

The growing demand for outpatient surgeries and increasing preference of specialized cardiac imaging devices are some of the major factors intended to cost-effective technology, which further drives the demand for heart tumor treatment in the European region.

Increasing prevalence of metastatic tumors, which require surgical procedures and growing medical tourism in Asia Pacific region are favoring the growth of this market. According to

the WHO estimate, 75% of the cardiovascular diseases occur are in low and middle income regions including Asia Pacific and the Middle East and Africa regions.


Chapter 1. Report Prologue
Chapter 2. 
Market Introduction

Chapter 3. Research Methodology

Chapter 4. Market Dynamics

Chapter 5. Market Factor Analysis

Chapter 6. Global Heart Tumor Market, By Type

Chapter 7. Global Heart Tumor Market, By Diagnosis

Chapter 8. Global Heart Tumor Market, By Treatment

Chapter 9. Global Heart Tumor Market, By Region

Chapter 10. Company Landscape

Chapter 11. Company Profiles

Chapter 12. MRFR Conclusion

Chapter 13. Appendix


GET DISCOUNT @ https://www.marketresearchfuture.com/check-discount/5065 .

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.


Media Contact
Company Name: Market Research Future
Contact Person: Akash Anand
Email: akash.anand@marketresearchfuture.com
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/heart-tumor-market-5065